Actively Recruiting
Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury
Led by University of Wisconsin, Madison · Updated on 2026-03-04
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether Cannabidiol (CBD), specifically Epidiolex, can improve urinary incontinence and related symptoms in adults who have recently experienced spinal cord injury (SCI). This pilot study focuses on people with neurogenic lower urinary tract dysfunction after spinal shock has resolved. The study aims to establish the feasibility of using CBD in this context and is sponsored by the University of Wisconsin, Madison. Participants will take a dose of 100 mg of purified CBD twice daily for 90 days. There is a single study group where all participants receive CBD treatment during this period. The study tracks adherence to the medication and monitors symptoms related to urinary incontinence and neurogenic bladder. During the 90-day treatment, participants will complete a 72-hour voiding diary and report any adverse events for up to 120 days. Researchers will assess changes in urinary incontinence episodes and symptoms, as well as how well participants follow the CBD regimen. Safety and treatment effects will be closely monitored, with the total participation lasting approximately 3 to 4 months.
CONDITIONS
Brief Title
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- History of supra-sacral spinal cord injury of any cause
- Experiencing 2 or more episodes of urinary incontinence per day outside of spinal shock
- Willing to participate in a drug intervention trial
- Able to speak English and provide consent and complete questionnaires
You will not qualify if you...
- History of intravesical Botox treatment
- Currently taking more than 15 mg of Oxybutynin or an equivalent anticholinergic medication for bladder symptoms
- Using cannabis in any form outside the study as confirmed by urine drug screen after 1 month washout if previously used
- Diagnosed with thought or mood disorders other than depression
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 90 days
Participants take 100mg of cannabidiol (CBD) twice daily to manage urinary symptoms related to spinal cord injury.
Regular visits during the 90 days as per study protocol
Duration - 30 days after treatment
Participants are monitored for adverse events and treatment adherence after completing the CBD regimen.
1 follow-up visit
Trial Site Locations
Total: 1 location
1
University of Wisconsin - Madison
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
M
Maria Flory
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here